Where does Femasys Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Femasys Inc. ranks #7,406 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Femasys Inc. hold?

Femasys Inc. holds 44 US utility patents granted between 2015 and 2025, spanning 5 technology areas.

What is Femasys Inc.'s Innovation Score?

Femasys Inc. has an Innovation Score of 38.1 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Femasys Inc. focus on?

Femasys Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 34 patents, ranking #557 of 7,127 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Femasys Inc.'s patent grant rate increasing or decreasing?

Femasys Inc.'s recent grant velocity is +38% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Femasys Inc.'s patents?

Femasys Inc.'s patents average 11.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Femasys Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Femasys Inc.

USPTO PatentsView assignee record - 44 granted patents across 5 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Femasys ranks #7,406 of 49,997 tracked US assignees by granted-patent volume, with 44 patents across 5 technology areas.

#7,406
of 49,997 US assignees by volume: Top 42%
by Innovation Score (38.1/100): 11.8
avg claims per patent: +38%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7406 · US Corporation #7,406 · 44 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 44 grants
UPPER-Q #7,406/49,997
PHOTO-FINISH Euro-Pro Operating
CPC-NARROW A61B · 5 areas
INNOV-THIN 38.1/100
CLAIMS-PAR 11.8 claims/avg
TYPE-USCORP US Corporation
VEL-UP +38% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Euro-Pro Operating LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Femasys’s 38.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.1 pts (34%) Velocity 10.0 pts (26%) Breadth 7.9 pts (21%) Claim depth 7.1 pts (19%)

Qualcomm Incorporated · highest

85
eYs3D Microelectronics · near

38
Femasys · this assignee

38
Power Forest… · near

38
Shenzhen Great… · near

38
Switchlab (Shanghai) · near

38
3D Lighting… · lowest

7

What this shows Femasys's Innovation Score is 38.1/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Femasys?

Each dot is one of Femasys’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Femasys’s own 11.8 claims/patent is at or below the 17.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Femasys vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Femasys's grants concentrate

Femasys Inc. is a focused PatentsView assignee: 5 CPC subclasses with 77.3% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2023 (8 grants) versus a trough of 1 in 2022. By volume, Femasys sits between Euro-Pro Operating LLC and GE Healthcare BioProcess R&D AB.

Femasys's three-year grant acceleration

Femasys Inc. shows 15 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Euro-pro Operating

44
Fastcap Systems

44
Fujifilm North Am…

44
Faurecia Emission…

44
Fertin Pharma A/S

44
Fette Compacting

44
GD Midea Environm…

44
GE Healthcare Bio…

44
Femasys ◀

44

What this shows Femasys holds 44 patents at rank #7,407, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Femasys

By rank, the assignees closest to #7,407 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Femasys's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Femasys, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Femasys ranks #557 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Power Forest Technology Corporation 38 eYs3D Microelectronics, Co. 38 Switchlab (Shanghai) Co., Ltd. 38 Shenzhen Great Power Innovation and Technology Enterprise Co., Ltd. 38

Femasys's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Femasys Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	6.8%
2016	3	6.8%
2017	4	9.1%
2018	3	6.8%
2019	3	6.8%
2020	3	6.8%
2021	4	9.1%
2022	1	2.3%
2023	8	18.2%
2024	6	13.6%
2025partial year	6	13.6%

Which technologies does Femasys Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 34

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 26

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 13

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 2

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Femasys Inc.'s patent record in context - here's where to go next.

Femasys Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 77.3% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #7,406 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Femasys Inc. against Euro-Pro Operating LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.